文献速递冠心病

ST段抬高型心肌梗死患者股动脉与桡动脉入路的安全性和有效性:SAFARI-STEMI随机临床试验

Safety and Efficacy of Femoral Access vs Radial Access in ST-Segment Elevation Myocardial Infarction: The SAFARI-STEMI Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2020-01-01

该多中心开放标签随机试验在加拿大5个PCI中心纳入2292例拟行直接PCI的STEMI患者,随机分为桡动脉入路(n=1136)或股动脉入路(n=1156)。再梗死、卒中及出血率亦无显著差异。

要点

  • 在STEMI直接PCI患者中,桡动脉与股动脉入路的30天全因死亡率无显著差异。
  • 次要终点(再梗死、卒中、出血)在两组间亦无统计学显著差异。
  • 试验因无效分析提前终止,不能 definitively 排除小的绝对差异。

核心结论

  • 对于拟行直接PCI的STEMI患者,桡动脉入路与股动脉入路在30天生存率及其他临床终点上无显著差异。

研究设计与样本

  • 多中心、开放标签、随机临床试验,在加拿大5个PCI中心进行,纳入2292例STEMI患者,随机分为桡动脉入路(n=1136)或股动脉入路(n=1156),随访30天,主要分析基于意向性治疗人群。

主要发现

  • 直接PCI实施率:桡动脉组95.2%(1082/1136),股动脉组95.9%(1109/1156)。

临床怎么用

  • 在STEMI直接PCI中,桡动脉入路与股动脉入路均可作为选择,需结合术者经验及患者具体情况决定。

局限性

  • 试验因无效分析提前终止,不能 definitively 排除终点上的小绝对差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Among patients with ST-segment elevation myocardial infarction (STEMI) referred for primary percutaneous coronary intervention (PCI), a survival benefit associated with radial access compared with femoral access remains controversial. OBJECTIVE: To assess whether there is a survival benefit when radial access is used instead of femoral access among patients with STEMI referred for primary PCI. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, open-label, randomized clinical trial was conducted at 5 PCI centers in Canada. In total, 2292 patients with STEMI referred for primary PCI were enrolled between July 2011 and December 2018, with a 30-day follow-up. The primary analyses were conducted based on the intention-to-treat population. INTERVENTIONS: Patients were randomized to radial access (n = 1136) or to femoral access (n = 1156) for PCI. MAIN OUTCOMES AND MEASURES: Initially, the primary outcome was bleeding, but this outcome was modified to 30-day all-cause mortality following the recommendation of the granting agency. Secondary outcomes included recurrent myocardial infarction, stroke, and Thrombolysis in Myocardial Infarction-defined major or minor bleeding. RESULTS: Among the 2292 patients enrolled, the mean (SD) age of the patients randomized to radial access was 61.6 (12.3) years and to femoral access was 62.0 (12.1) years, with 883 male patients in the radial access and 901 male patients in the femoral access group. The trial was stopped early following a futility analysis. Primary PCI was performed in 1082 of 1136 patients (95.2%) in the radial access group and 1109 of 1156 patients (95.9%) in the femoral access group. Bivalirudin was administered to 1001 patients (88.1%) in the radial access group and to 1068 patients (92.4%) in the femoral access group, whereas glycoprotein IIb/IIIa inhibitors were administered in only 69 patients (6.1%) in the radial access group and 68 patients (5.9%) in the femoral access group. A vascular closure device was used in 789 patients (68.3%) in the femoral group. The primary outcome, 30-day all-cause mortality, occurred in 17 patients (1.5%) assigned to radial access and in 15 patients (1.3%) assigned to femoral access (relative risk [RR], 1.15; 95% CI, 0.58-2.30; P = .69). There were no significant differences between patients assigned to radial and femoral access in the rates of reinfarction (1.8% vs 1.6%; RR, 1.07; 95% CI, 0.57-2.00; P = .83), stroke (1.0% vs 0.4%; RR, 2.24; 95% CI, 0.78-6.42; P = .12), and bleeding (1.4% vs 2.0%; RR, 0.71; 95% CI, 0.38-1.33; P = .28). CONCLUSIONS AND RELEVANCE: No significant differences were found for survival or other clinical end points at 30 days after the use of radial access vs femoral access in patients with STEMI referred for primary PCI. However, small absolute differences in end points cannot be definitively refuted given the premature termination of the trial. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01398254.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Le May M, Wells G, So D, et al. Safety and Efficacy of Femoral Access vs Radial Access in ST-Segment Elevation Myocardial Infarction: The SAFARI-STEMI Randomized Clinical Trial. JAMA Cardiol. 2020. PMID: 31895439. doi:10.1001/jamacardio.2019.4852

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。